Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Petah Tikva
Clinical trial register · Israel

Clinical Trials in Petah Tikva, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2438 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2438
Studies in scope
all four open statuses
1243
Recruiting now
open to new participants
461
Lead sponsors
across recruiting studies
Top sites
Jerusalem 52 Haifa 49 Ramat Gan 43 Petah Tikva 40 Kfar Saba 39
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC63 AbbVie45 AstraZeneca40 Janssen Research & Development, LLC37 Eli Lilly and Company29 Clear sponsor filter
Site location
Jerusalem52 Haifa49 Ramat Gan43 Petah Tikva40 Kfar Saba39
All 21 locations
Target enrolment
to

Trials with a site in Petah Tikva

40 of 2438 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Recruiting
AstraZeneca
Phase 2
24
Haifa, Kfar Saba, Petah Tikva, Ramat Gan
2026-08-31
Recruiting
AstraZeneca
Phase 3
500
Holon, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv
2026-08-24
Recruiting
AstraZeneca
Phase 3
600
Haifa, Jerusalem, Kfar Saba, Petah Tikva
2026-08-12
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Haifa, Holon, Petah Tikva
2026-07-24
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Ashkelon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot
2026-06-11
Recruiting
AstraZeneca
Phase 3
670
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2026-05-04
Recruiting
AstraZeneca
Phase 3
700
Afula, Beersheba, Hadera, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva
2025-08-06
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
14
Petah Tikva
2025-04-17
Recruiting
AstraZeneca
Phase 3
11,300
Beersheba, Be’er Ya‘aqov, Haifa, Herzelia, Holon, Jerusalem, Petah Tikva, Ramat Gan
2025-03-14
Recruiting
AstraZeneca
Phase 3
5,000
Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva
2025-03-03
Active, closed
AstraZeneca
Phase 3
768
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2024-10-04
Recruiting
AstraZeneca
Phase 3
788
Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2024-08-01
Active, closed
AstraZeneca
Phase 3
2,554
Ashkelon, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
2024-03-29
Active, closed
AstraZeneca
Phase 3
1,835
Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Rehovot
2023-11-07
Recruiting
AstraZeneca
Phase 3
3,527
Afula, Ashkelon, Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan
2022-12-13
Active, closed
AstraZeneca
Phase 3
368
Holon, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
2022-11-10
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Petah Tikva, Ramat Gan, Tel Aviv
2022-05-23
Active, closed
AstraZeneca
Phase 3
1,035
Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2022-03-25
Active, closed
AstraZeneca
Phase 3
148
Haifa, Petah Tikva
2021-10-28
Active, closed
AstraZeneca
Phase 3
315
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan
2021-06-30
Active, closed
AstraZeneca
Phase 3
1,157
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2021-04-26
Active, closed
AstraZeneca
Phase 3
358
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2020-12-16
Active, closed
AstraZeneca
Phase 3
185
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2020-08-04
Active, closed
AstraZeneca
Phase 3
866
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2020-07-24
Active, closed
AstraZeneca
Phase 3
134
Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
2020-07-20
Active, closed
AstraZeneca
Phase 3
1,012
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tsrifin
2020-07-13
Active, closed
AstraZeneca
Phase 2
240
Jerusalem, Nahariya, Petah Tikva
2020-04-22
Active, closed
AstraZeneca
Phase 3
818
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2020-04-16
Active, closed
AstraZeneca
Phase 3
724
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-03-06
Active, closed
AstraZeneca
Phase 3
1,063
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2018-11-16
Active, closed
AstraZeneca
Phase 3
1,246
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2018-09-27
Active, closed
AstraZeneca
Phase 2
528
Haifa, Kfar Saba, Petah Tikva, Ramat Gan
2017-12-18
Active, closed
AstraZeneca
Phase 3
987
Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2017-03-27
Active, closed
AstraZeneca
Phase 1/2
264
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2016-03-17
Active, closed
AstraZeneca
Phase 3
953
Beersheba, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,837
Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2014-04-22
Active, closed
AstraZeneca
Phase 3
510
Beersheba, Haifa, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2013-09-25
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Haifa, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
2013-08-26
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-israel/city/petah-tikva

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,438 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Petah Tikva that also match the filters currently applied.

How many clinical trials are recruiting in Petah Tikva?

12 of the 40 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 28 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Petah Tikva), 40 studies
PhaseStudiesRecruitingShare
Phase 3341085%
Phase 24210%
Observational102.5%
Phase 1/2102.5%

Most active sponsors

Lead sponsors with the most studies (Petah Tikva)
Lead sponsorStudiesRecruiting
AstraZeneca4012
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.